



Sheet 1 of 3

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60053	SERIAL NO. 10/823,964
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Bam, <i>et al.</i>	
		FILING DATE 14 April 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CMW	2003171284	09/11/03	Cox, <i>et al.</i>	514	12	
↓	2003191056	10/09/03	Walker, <i>et al.</i>	514	12	
↓	2003195154	10/16/03	Walker, <i>et al.</i>	514	12	
↓	6,602,498	08/05/03	Xiaoming Shen	424	78.08	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
CMW	WO99/03887	01/28/99	PCT	—	—		
↓	WO2002/077218	10/03/02	PCT	—	—		
↓	WO2001/003737	01/18/01	PCT	—	—		
↓	WO2001/62827	08/30/01	PCT	—	—		
↓	WO2000/042175	07/20/00	PCT	—	—		
↓	WO2001/087925	11/22/01	PCT	—	—		
↓	EP0712931	05/22/96	EPO	—	—		
↓	EP0692536	01/17/96	EPO	—	—		
↓	EP0974600	09/19/01	EPO	—	—		
↓	EP0819757	01/21/98	EPO	—	—		
↓	EP0816499	01/07/98	EPO	—	—		
↓	EP0845530	06/03/98	EPO	—	—		
↓	EP0859052	08/19/98	EPO	—	—		
↓	EP0821005	01/28/98	EPO	—	—		
↓	EP0767178	04/09/97	EPO	—	—		
↓	EP110969A1	06/27/01	EPO	—	—		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60053	SERIAL NO. 10/823,964
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Barn, <i>et al.</i>	
		FILING DATE 14 April 2004	GROUP Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CMW		Pomroy, <i>et al.</i> , "Solubilization of Hydrophobic Peptides by Reversible Cysteine PEGylation," <i>Biochemical and Biophysical Research Communications</i> , 245 : 618-621 (1998).
		Albrecht, <i>et al.</i> , "Production of Soluble ScFVS with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand," <i>Bioconjugate Chem.</i> , 15 : 16-26 (2004).
		Sato, <i>et al.</i> , "Transglutaminase-Mediated Dual and Site-Specific Incorporation of Poly(ethylene glycol) Derivatives into a Chimeric Interleukin-2," <i>Bioconjugate Chem.</i> , 11 : 502-509 (2000).
		Manjula, <i>et al.</i> , "Site-Specific PEGylation of Hemoglobin at Cys-93(β): Correlation between the Colligative Properties of the PEGylated Protein and the Length of the Conjugated PEG Chain," <i>Bioconjugate Chem.</i> , 14 : 464-472 (2003).
		Pettit, <i>et al.</i> , "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling," <i>The Journal of Biological Chemistry</i> , 272 (4): 2312-2318 (1997).
		Yang, <i>et al.</i> , "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation," <i>Protein Engineering</i> , 16 (10): 761-770 (2003).
		Uchio, <i>et al.</i> , "Site-specific insulin conjugates with enhanced stability and extended action profile," <i>Advanced Drug Delivery Reviews</i> , 35 : 289-306 (1999).
		Stimmel, <i>et al.</i> , "Site-specific Conjugation on Serine \rightarrow Cysteine Variant Monoclonal Antibodies," <i>The Journal of Biological Chemistry</i> , 275 (39): 30445-30450 (2000).
		Lee, <i>et al.</i> , "Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A Comparison of Conjugation Chemistries and Compounds," <i>Bioconjugate Chem.</i> , 10 : 973-981 (1999).
		Cantin, <i>et al.</i> , "Polyethylene Glycol Conjugation at Cys ²³² Prolongs the Half-Life of α 1 Proteinase Inhibitor," <i>American Journal of Respiratory Cell Molecular Biology</i> , 27 : 659-665 (2002).
		Andrew P. Chapman, "PEGylated antibodies and antibody fragments for improved therapy: a review," <i>Advanced Drug Delivery Reviews</i> , 54 : 531-545 (2002).
		Yoshioka, <i>et al.</i> , "Optimal site-specific PEGylation of mutant RNF- α improves its antitumor potency," <i>Biochemical and Biophysical Research Communications</i> , 315 : 808-814 (2004).
		Lee, <i>et al.</i> , "N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor," <i>Pharmaceutical Research</i> , 20 (5): 818-825 (2003).
		Clark, <i>et al.</i> , "Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol," <i>The Journal of Biological Chemistry</i> , 271 (36): 21969-21977 (1996).
✓		Haruya Sato, "Enzymatic procedure for site-specific pegylation of proteins," <i>Advanced Drug Delivery Reviews</i> , 54 : 487-504 (2002).

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60053	SERIAL NO. 10/823,964
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Bam, <i>et al.</i>	
		FILING DATE 14 April 2004	GROUP Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CMW		Hinds, <i>et al.</i> , "Effects of PEG conjugation on insulin properties," <i>Advanced Drug Delivery Reviews</i> , 54: 505-530 (2002).
		Leong, <i>et al.</i> , "Adapting Pharmacokinetic Properties of a Humanized Anti-Interleukin-8 Antibody for Therapeutic Applications Using Site-Specific Pegylation," <i>Cytokine</i> , 16 (3): 106-119 (2001).
		Seely, <i>et al.</i> , "Issues encountered in the production of site-specific mono-PEGylated therapeutic proteins," <i>Polymer Preprints (American Chemical Society, Division of Polymer Chemistry)</i> , 38(1): 572-573 (1997).
		Zalipsky, <i>et al.</i> , "Reversible PEGylation: thiolytic regeneration of active protein from its polymer conjugates," <i>Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium</i> , San Diego, CA, June 9-14, 2001, pp. 953-954.
EXAMINER /Cherie Woodward/		DATE CONSIDERED 10/03/2006
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

document1